Grafa News and Videos — Page 51

Immix Biopharma (NASDAQ:IMMX) reported interim results from its Phase 2 NEXICART-2 clinical trial evaluating NXC-201 in patients with relapsed or refractory AL amyloidosis.

Turbo Energy (NASDAQ:TURB) reported first-half 2026 financial results, with significant revenue growth and a return to profitability.

Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.

Caterpillar (NYSE:CAT) announced an agreement to acquire John Fabick Tractor Company, an independent Cat dealer serving customers across parts of the Midwest United States.

PowerBank (NASDAQ:PBK) reported fiscal 2026 financial results, with lower revenue but improved gross margins and a narrower net loss.

SLB (NYSE:SLB) announced that its OneSubsea joint venture has been awarded a contract by ExxonMobil Moçambique, Limitada, on behalf of its Area 4 partners, to deliver subsea production systems for the first phase of the offshore Rovuma LNG project in Mozambique.

Aldeyra Therapeutics (NASDAQ:ALDX) announced plans to submit a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration (FDA) seeking review of the agency’s decision not to approve reproxalap, its investigational therapy for dry eye disease.

Unicycive Therapeutics (NASDAQ:UNCY) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate, an investigational treatment for hyperphosphatemia in patients receiving dialysis.

uniQure (NASDAQ:QURE) reported additional Phase I/II data for ifezuntirgene inilparvovec, its investigational gene therapy for Huntington’s disease, with follow-up results extending to 36 and 48 months.

Invivyd (NASDAQ:IVVD) reported Phase 3 LIBERTY trial results showing that its investigational COVID-19 antibody product VYD2311 demonstrated fewer reported adverse events compared with an mRNA COVID-19 vaccine.